MindMaze Therapeutics Holding (XSWX:MMTX) Other Operating Expense: CHF Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:MMTX MindMaze Therapeutics Holding SA XSWX:MMTX
4 GF Score
Price CHF0.16
! 2 Warning Signs
View Full Analysis

What is MindMaze Therapeutics Holding Other Operating Expense?

MindMaze Therapeutics Holding XSWX:MMTX +3.67% 4 Other Operating Expense is CHF Mil as of Dec. 2025. GuruFocus rates XSWX:MMTX with a GF Score™ of 4/100. The stock has 2 warning signs investors should review.

MindMaze Therapeutics Holding's Other Operating Expense for the six months ended in Dec. 2025 was CHF0.00 Mil. MindMaze Therapeutics Holding does not have enough years/quarters to calculate its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025.

MindMaze Therapeutics Holding Other Operating Expense Historical Data

* Premium members only.

The historical data trend for MindMaze Therapeutics Holding's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindMaze Therapeutics Holding Other Operating Expense Chart

MindMaze Therapeutics Holding Annual Data
Trend Dec24 Dec25
Other Operating Expense
0.00 0.00

MindMaze Therapeutics Holding Semi-Annual Data
Dec24 Dec25
Other Operating Expense 0.00 0.00
XSWX:MMTX
4GF Score
MindMaze Therapeutics Holding SA XSWX:MMTX
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindMaze Therapeutics Holding Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of CHF Mil mean?
MindMaze Therapeutics Holding (XSWX:MMTX) has a Other Operating Expense of CHF Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on MindMaze Therapeutics Holding and its competitors.
Is MindMaze Therapeutics Holding's Other Operating Expense too high?
MindMaze Therapeutics Holding's current Other Operating Expense is CHF Mil. Overall, MindMaze Therapeutics Holding has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's Other Operating Expense compare to VRTX and REGN?
MindMaze Therapeutics Holding's Other Operating Expense of CHF Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on MindMaze Therapeutics Holding and its competitors. MindMaze Therapeutics Holding's current Other Operating Expense is CHF Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (XSWX:MMTX) has a current Other Operating Expense of CHF Mil. The current Other Operating Expense is CHF Mil. MindMaze Therapeutics Holding's overall GF Score™ is 4/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For MindMaze Therapeutics Holding (XSWX:MMTX), the current Other Operating Expense is CHF Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MindMaze Therapeutics Holding Business Description

Other Exchanges RLFTY:USAMMTXz:UK
Address Avenue de Secheron 15, Geneva, CHE, 1202
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
4GF Score

Get the complete analysis for XSWX:MMTX

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF0.16
Price